Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review

Gambardella, Alessio; Licata, Gaetano; Sohrt, Anne

doi:10.1007/s13555-021-00559-z

Cited by 17 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Initiation of an adjuvant treatment or dose escalation (by shortening the dosing interval of a biologic drug) frequently occurs in real‐world biologic treatment processes usually because of inadequate primary response or loss of efficacy over time 27 . Although these treatment modifications can have safety concerns, none of the patients in our study experienced treatment‐modification‐related adverse events, and most of them gained/regained good PASI scores.…”

Section: Discussionmentioning

confidence: 85%

Ixekizumab treatment in patients with moderate‐to‐severe plaque psoriasis in a real‐world clinical setting

Öğüt

Yıldırım

Erbağcı

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Psoriasis is a complex, chronic, and immune-mediated inflammatory disease affecting almost 2.5% of the world population. 1 Psoriasis is primarily a dermatological condition that is most often associated with other comorbidities, including psoriatic arthritis, hypertension, diabetes mellitus, obesity, psychiatric disorders, and systemic inflammation beyond the skin. Effective, safe, and long-term management of psoriasis is important in controlling skin lesions and preventing metabolic and psychiatric comorbidities. 2 New treatment

show abstract

Section: Discussionmentioning

confidence: 85%

Ixekizumab treatment in patients with moderate‐to‐severe plaque psoriasis in a real‐world clinical setting

Öğüt

Yıldırım

Erbağcı

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…KEGG was widely employed to screen biological pathways (31). DO enrichment analysis was commonly used to identify large-scale disease enrichment research by clusterProfiler, GSEABase (version 1.58.0) (32), DOSE (version 3.22.0) (33), and enrichplot package in R language (adjusted P<0.05). GSEA analysis was applied to investigate potential differences in biological processes and signaling pathways in GEO merged dataset and TCGA-PRAD cohort by the 'clusterProfiler and enrichplot package' in R software.…”

Section: Gene Ontology (Go) Biological Function the Kyotomentioning

confidence: 99%

LTBP2 inhibits prostate cancer progression and metastasis via the PI3K/AKT signaling pathway

Zhang

Tian

Cheng³

et al. 2022

Exp Ther Med

View full text Add to dashboard Cite

Biochemical recurrence (BCR) is a cause of concern in advanced prostate cancer (PCa). Thus, novel diagnostic biomarkers are required to improve clinical care. However, research on PCa immunotherapy is also scarce. Hence, the present study aimed to explore promising BCR-related diagnostic biomarkers, and their expression pattern, prognostic value, immune response effects, biological functions, and possible molecular mechanisms were evaluated. GEO datasets (GSE46602, GSE70768, and GSE116918) were downloaded and merged as the training cohort, and differential expression analysis was performed. Lasso regression and SVM-RFE algorithm, as well as PPI analysis and MCODE algorithm, were then applied to filter BCR-related biomarker genes. The CIBERSORT and estimation of stromal and immune cells in malignant tumor tissues using expression data (ESTIMATE) methods were used to calculate the fractions of tumorinfiltrating immune cells. GO/DO enrichment analyses were used to identify the biological functions. The expression of latent transforming growth factor β-binding protein 2 (LTBP2) was determined by RT-qPCR and western blotting. The role of LTBP2 in PCa was determined by CCK-8, Transwell, and the potential mechanism was investigated by KEGG and GSEA and confirmed by western blotting. In total, 44 BCR-related differentially expressed genes (DEGs) in the training cohort were screened. LTBP2 was found to be a diagnostic biomarker of BCR in PCa and was associated with CD4 + T-cell infiltration and response to anti-PD-1/PD-L1 immunotherapy. Subsequently, using the ESTIMATE algorithm, it was identified that LTBP2 was associated with the tumor microenvironment and could be a predictor of the clinical benefit of immune checkpoint blockade. Finally, the expression and biological function of LTBP2 were evaluated via cellular experiments. The results showed that LTBP2 was downregulated in PCa cells and inhibited PCa proliferation and metastasis via the PI3K/AKT signaling pathway in vitro. In conclusion, LTBP2 was a promising diagnostic biomarker of BCR of PCa and had an important role in CD4 + T-cell recruitment. Moreover, it was associated with immunotherapy in patients with PCa who developed BCR, and it inhibited PCa proliferation and metastasis via the PI3K/AKT signaling pathway in vitro.

show abstract

“…[1][2][3][4] Although no guidelines exist to date for the off-label use of biologic dose modification, it is a common clinical practice in the long-term treatment of moderate-to-severe plaque psoriasis, in which escalation is more frequently reported than reduction for biologic agents. [5][6][7][8] The information about SEC dose reduction (SEC-DR) in psoriasis treatment in a real-life dermatological setting is limited and only marginally mentioned. 9,10 Only two studies informed about dose adjustment for secukinumab: One of them showed that 52% of patients initiated on a lower dose (150 mg) than that recommended under Summary of Product Characteristic (SPC) 9 ; the other only focused on dose escalation.…”

Section: Introductionmentioning

confidence: 99%

“…The anti‐IL‐17A monoclonal antibody secukinumab (SEC) has shown long‐lasting efficacy Psoriasis Area and Severity Index (PASI) 90/100 responses and safety in moderate‐to‐severe plaque psoriasis in several clinical trials and daily practice 1–4 . Although no guidelines exist to date for the off‐label use of biologic dose modification, it is a common clinical practice in the long‐term treatment of moderate‐to‐severe plaque psoriasis, in which escalation is more frequently reported than reduction for biologic agents 5–8 . The information about SEC dose reduction (SEC‐DR) in psoriasis treatment in a real‐life dermatological setting is limited and only marginally mentioned 9,10 .…”

Section: Introductionmentioning

confidence: 99%

Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting

Daudén,

Escario,

Martos‐Cabrera

et al. 2024

Int J Dermatology

View full text Add to dashboard Cite

BackgroundBiological therapy dose modification is a common practice in the long‐term treatment of plaque psoriasis.ObjectiveThe objective of the study was to determine prevalence, characteristics of patients, effectiveness, treatment survival of secukinumab dose reduction (SEC‐DR) strategy and assess its safety and cost implications.MethodsA retrospective, observational, multicenter cohort study was conducted in patients with plaque psoriasis treated with secukinumab and up to 2 years of follow‐up.ResultsIn 63/347 patients with an initial standard dose regimen, SEC‐DR was tried at any moment in 18.2% of them after sustained response. In 51 patients, the interval between administrations was increased while in 12 patients, monthly dose was reduced to 150 mg. Successful SEC‐DR was achieved in 77.8% of the patients, with sustained PASI response to the end of the study. Survival of secukinumab treatment and safety profile were not compromised by DR. The use of DR saved 33% of the cost, including failures in which standard treatment was resumed.LimitationsThe proper of the study designed and the arbitrary definition of “DR success.”ConclusionOff‐label SEC‐DR strategy was used in patients with sustained response to standard dose regimen; this strategy showed long‐term efficacy without compromising treatment survival or worsening the safety profile while also being cost saving.

show abstract

Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review

Cited by 17 publications

References 32 publications

Ixekizumab treatment in patients with moderate‐to‐severe plaque psoriasis in a real‐world clinical setting

Ixekizumab treatment in patients with moderate‐to‐severe plaque psoriasis in a real‐world clinical setting

LTBP2 inhibits prostate cancer progression and metastasis via the PI3K/AKT signaling pathway

Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting

Contact Info

Product

Resources

About